Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme

Phase 2

Completed

• Conditions: Glioblastoma Multiforme; Glioblastoma; Astrocytoma, Grade IV; GBM; Malignant Glioma
• Interventions: Biological: unpulsed PBMC and saline; Biological: pp65-shLAMP DC with GM-CSF; Biological: pp65-flLAMP DC with GM-CSF; Drug: Saline; Drug: Td

• Registration Number: NCT02465268
• Lead Sponsor: University of Florida

Brief Summary

The purpose of this research study is to determine if an investigational dendritic cell vaccine, called pp65 DC, is effective for the treatment of a specific type of brain tumor called glioblastoma (GBM) when given with stronger doses of routine chemotherapy.

Detailed Description

Dendritic cells (DC) are involved in activating, or turning-on, your body's immune system. Your immune system helps guard your body from germs, viruses, and other threats. Although dendritic cells are very strong, the number of them in the body is not high enough to cause a powerful immune response; therefore, more DC are made in a laboratory with cells collected from an individual's blood.

In this study, we will make a vaccine that we hope will educate immune cells to target the pp65 antigen, a type of immune marker in GBM, thus resulting in what we call the pp65 DC vaccine. Use of a vaccine that activates your immune system is a type of immunotherapy. It is hoped that by giving the pp65 DC vaccine as a shot under the skin, the immune system will be activated to attack tumor cells in the brain while leaving normal cells alone.

To see if the pp65 DC vaccine is effective for the treatment of GBM, subjects will be assigned to different treatment groups. Two groups of subjects will receive the pp65 DC vaccine and one group will receive a placebo.

Study Timeline

• Study First Submitted: 2015-05-27
• Study First Submitted QC: 2015-06-03
• Study First Posted: 2015-06-08
• Study Start: 2016-08-09
• Primary Completion: 2023-11-30
• Study Completion: 2023-11-30
• Status Verified: 2024-10
• Last Update Submitted: 2024-10-07
• Last Update Posted: 2024-10-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 175

Inclusion Criteria

To be assessed at study enrollment prior to standard of care chemo-radiation therapy:

• Age ≥ 18 years.
• Histopathologically proven newly-diagnosed de novo GBM (WHO Grade IV glioma)
• The tumor must have a supratentorial component.
• Must have undergone definitive surgical resection of tumor with less than approximately 3cm x 3cm residual enhancing tumor as product of longest perpendicular planes by MRI.
• Recovery from the effects of surgery, postoperative infection, and other complications.
• Diagnostic contrast-enhanced MRI or CT scan of the brain preoperatively and postoperatively.
• Karnofsky Performance Status of ≥ 70.
• Signed informed consent.
• For females of childbearing potential, negative serum pregnancy test.
• Women of childbearing potential and male participants must be willing to practice adequate contraception throughout the study and for at least 24 weeks after the last dose of study drug.

To be assessed prior to initiation of adjuvant TMZ:

• Must have completed RT (targeted total dose of 59.4-60.0 Gy over ≤ 7 weeks) and concomitant TMZ (targeted dose of 75mg/m2/d for ≤ 49 days) therapy without significant toxicity that persisted over 4 weeks.
• History & physical with neurologic examination prior to initiation of adjuvant TMZ.
• For patients receiving steroids, daily dose must be ≤ 4 mg.
• CBC with differential with adequate bone marrow function.
• Adequate renal function.
• Adequate hepatic function.

Abbreviated

Read More

Exclusion Criteria

To be verified in order to randomize subject:

• Prior invasive malignancy unless disease free for ≥ 3 years.
• Metastases detected below the tentorium or beyond the cranial vault and leptomeningeal involvement.
• Recurrent or multifocal malignant gliomas.
• HIV, Hepatitis B, or Hepatitis C seropositive.
• Known active infection or immunosuppressive disease.
• Prior chemotherapy or radiosensitizers (including Gliadel wafers) for cancers of the head and neck region.
• Prior radiotherapy to the head or neck, resulting in overlap of radiation fields.
• Severe, active co-morbidity.
• Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception for the entire study period.
• Pregnant or lactating women.
• Prior allergic reaction to temozolomide, GM-CSF or Td.
• Prior history of brachial neuritis or Guillain-Barré syndrome.
• Patients treated on any other therapeutic clinical protocols within 30 days prior to study entry.

To be assessed prior to initiation of adjuvant TMZ:

• Did not start radiation therapy and temozolomide within 7 weeks of surgery.
• Progression of disease as defined by modified RANO criteria.
• More than 45 days after completion of radiation therapy and temozolomide

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
pp65-flLAMP DC with GM-CSF and Td	pp65-flLAMP DC with GM-CSF	Given under the skin at day 22-24 after the first temozolomide cycle then at 2 week intervals. Doses 4-10 will be given on day 22-24 of each temozolomide cycle. Doses will continue until a total of 10 or until progression or unacceptable toxicity.
unpulsed PBMC and Saline	unpulsed PBMC and saline	Given under the skin at day 22-24 after the first temozolomide cycle then at 2 week intervals. Doses 4-10 will be given on day 22-24 of each temozolomide cycle. Doses will continue until a total of 10 or until progression or unacceptable toxicity.
pp65-shLAMP DC with GM-CSF and Td	pp65-shLAMP DC with GM-CSF	Given under the skin at day 22-24 after the first temozolomide cycle then at 2 week intervals. Doses 4-10 will be given on day 22-24 of each temozolomide cycle. Doses will continue until a total of 10 or until progression or unacceptable toxicity.
unpulsed PBMC and Saline	Saline	Given under the skin at day 22-24 after the first temozolomide cycle then at 2 week intervals. Doses 4-10 will be given on day 22-24 of each temozolomide cycle. Doses will continue until a total of 10 or until progression or unacceptable toxicity.
pp65-shLAMP DC with GM-CSF and Td	Td	Given under the skin at day 22-24 after the first temozolomide cycle then at 2 week intervals. Doses 4-10 will be given on day 22-24 of each temozolomide cycle. Doses will continue until a total of 10 or until progression or unacceptable toxicity.
pp65-flLAMP DC with GM-CSF and Td	Td	Given under the skin at day 22-24 after the first temozolomide cycle then at 2 week intervals. Doses 4-10 will be given on day 22-24 of each temozolomide cycle. Doses will continue until a total of 10 or until progression or unacceptable toxicity.

Primary Outcome Measures

Name	Time	Method
Comparison of overall survival (OS) between the active treatment group (Arms 1 and 2 combined) and the control group (Arm 3)	From date of first vaccine until the date of death, up to 48 months	Kaplan-Meier survival curves and the log rank test will be used to characterize and compare OS in patients who received pp65-LAMP mRNA DC vaccine (Arms 1 and 2) and in control patients (Arm 3). OS will be defined as the time between first vaccination and death and will be censored at the last follow-up if death has not occurred.

Secondary Outcome Measures

Name	Time	Method
Comparison of progression-free survival between the active treatment group (Arms 1 and 2 combined) and the control group (Arm 3)	From date of first vaccine until time disease progression or death without prior progression/recurrence, up to 48 months	Kaplan-Meier survival curves and the log rank test will be used to characterize and compare PFS in patients who received pp65-LAMP mRNA DC vaccine (Arms 1 and 2) and in control patients (Arm 3). PFS is defined as the time between first vaccination and first documentation of either disease progression/recurrence, or death without prior progression/recurrence.
ELISPOT assay	initial leukapheresis, prior to vaccines 1-3, second leukapheresis	Frequency of interferon secreting cells in PBMCs
Flow cytometric analysis	initial leukapheresis, prior to vaccines 1-3, second leukapheresis	Percentage of circulating cellular subsets of T cells, NK cells and regulatory cells within PBMCs
Cytokine array analysis	initial leukapheresis, prior to vaccines 1-3, second leukapheresis	Concentration (pg/mL) of serum cytokines as measured by multiplex array

Trial Locations

Locations (3)

Duke University Medical Center; 🇺🇸 Durham, North Carolina, United States

Orlando Health; 🇺🇸 Orlando, Florida, United States

University of Florida; 🇺🇸 Gainesville, Florida, United States